Biotech stocks have been dramatically outperforming the broader market, but that doesn't mean they're free of risk. Here are three types of risks all biotech stocks face.
Biotech stocks have nearly doubled the return of the S&P 500 since March 2009. Can the run higher continue, or have valuations among biotech stocks entered bubble territory?
One report claims Internet of Things devices will grow from nearly 4.9 billion units installed in 2015 to 25 billion by 2020. Yet, in spite of this rapid growth potential, these three stocks could leave the Internet of Things in the dust.
Just because these stocks are near their highs doesn't mean you should hang on to them.
When it comes to the most profitable businesses in biotech, these 10 companies are the cream of the crop.
Mega-cap stocks are generally profitable and overflowing with free cash, leading many to pay handsome dividends. However, these three mega-cap stocks aren't currently paying a dividend -- and if their management teams are smart, they'll keep it that way for many years to come!
The hot burrito roller's stock cools down, and it was the right move.
Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.
Everyone's looking for the next hot burrito roller, but it may be closer than you think.
Just because these three companies trade north of $100 doesn't mean they're necessarily overvalued. Here are three triple-digit stocks with significant upside potential.